ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,092.30
0.00%
S&P ASX All Technology
3,179.00
0.00%
Brent Oil
81.44
3.66%
US Dollar vs AUD
1.52835
-0.03%
Bitcoin
64,822.53
-2.04%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Nurix Therapeutics Inc (NRIX)

  7. Nurix Therapeutics Inc (NRIX) News

NRIX

Nurix Therapeutics (NRIX)

Nurix Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NRIX
DateTimeSourceHeadlineSymbolCompany
31/07/202409:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
31/07/202409:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
31/07/202409:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
12/07/202406:45Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NRIXNurix Therapeutics Inc
12/07/202406:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NRIXNurix Therapeutics Inc
12/07/202406:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRIXNurix Therapeutics Inc
12/07/202406:00GlobeNewswire Inc.Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate UpdateNASDAQ:NRIXNurix Therapeutics Inc
08/07/202421:00GlobeNewswire Inc.Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) DayNASDAQ:NRIXNurix Therapeutics Inc
17/06/202421:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRIXNurix Therapeutics Inc
16/06/202419:30GlobeNewswire Inc.Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)NASDAQ:NRIXNurix Therapeutics Inc
14/06/202408:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
13/06/202409:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
12/06/202406:06Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:NRIXNurix Therapeutics Inc
10/06/202421:00GlobeNewswire Inc.Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)NASDAQ:NRIXNurix Therapeutics Inc
06/06/202408:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
04/06/202408:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
04/06/202406:58Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NRIXNurix Therapeutics Inc
29/05/202421:00GlobeNewswire Inc.Nurix Therapeutics to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:NRIXNurix Therapeutics Inc
28/05/202421:00GlobeNewswire Inc.Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical OfficerNASDAQ:NRIXNurix Therapeutics Inc
21/05/202421:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRIXNurix Therapeutics Inc
21/05/202409:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
21/05/202409:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
21/05/202406:00GlobeNewswire Inc.Nurix Therapeutics Announces Board Chair TransitionNASDAQ:NRIXNurix Therapeutics Inc
15/05/202400:00GlobeNewswire Inc.Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)NASDAQ:NRIXNurix Therapeutics Inc
07/05/202421:00GlobeNewswire Inc.Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare ConferenceNASDAQ:NRIXNurix Therapeutics Inc
17/04/202408:21GlobeNewswire Inc.Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:NRIXNurix Therapeutics Inc
12/04/202413:38GlobeNewswire Inc.Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public OfferingNASDAQ:NRIXNurix Therapeutics Inc
12/04/202406:00GlobeNewswire Inc.Nurix Therapeutics Announces Proposed Public OfferingNASDAQ:NRIXNurix Therapeutics Inc
10/04/202421:00GlobeNewswire Inc.Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate UpdateNASDAQ:NRIXNurix Therapeutics Inc
10/04/202403:15GlobeNewswire Inc.Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell MalignanciesNASDAQ:NRIXNurix Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NRIX

Your Recent History

ASX
BHP
BHP
ASX
XFL
S&P ASX 50
SPI
SP500
S&P 500
NASDAQ
NVDA
NVIDIA
NASDAQ
AMZN
Amazon.com
NYSE
XOM
Exxon Mobil
ASX
NAB
National Australia Bank
ASX
CSL
CSL
NASDAQ
QQQ
Invesco QQQ Trust Series 1
ASX
WOW
Woolworths
NASDAQ
TSLA
Tesla
ASX
ORG
Origin Energy
ASX
XMM
S&P ASX 300 Metals and M...
ASX
WDC
Westfield
ASX
WES
Wesfarmers
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved